Trade NanoViricides, Inc. - NNVC CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.1578
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$1.08)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.03)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$1.08)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.03)

Key Stats

• Prev. Close: 1.4961
• Open: 1.5061
• 1-Year Change: -9.59%
• Day's Range: 1.4861 - 1.5361

Trade NanoViricides, Inc. - NNVC

About NanoViricides Inc

NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.

Financial summary

BRIEF: For the six months ended 31 December 2021, NanoViricides Inc revenues was not reported. Net loss decreased 2% to $4.5M. Lower net loss reflects General and administrative decrease of 21% to $1.2M (expense), Interest expense decrease of 96% to $4K (expense), Loss on disposal of property and equip. decrease from $2K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.44 to -$0.39.

Equity composition

Common Stock $.001 Par, 2/11, 300M auth., 139,906,601 issd. Insider owns 30.00%. Conv. Pref. Stock Class A $.001 Par, 10M auth., 7,593,750 issd. 09/13, 1-for-3.5 Reverse Stock split.